The question is not only whether the Respiratory Vision is liked. It is whether Asthma and COPD teams can use it without losing disease-area relevance.
Tezspire can tell a broad, low-friction choice story. Nucala and the IL-5s can use familiar eosinophil logic. Exdensur can focus attention on convenience. Inertia can still win by delaying escalation.
Dupixent has a richer story, but richer can become harder to repeat.
Dupixent has breadth, outcomes, Type 2 authority, and cross-disease potential.
If the agenda is too broad, markets may struggle to repeat the core clearly. If it is too narrow, the Respiratory Vision loses its platform value.
But they do need to ladder up to the same Respiratory Vision.
The work is to define what must stay consistent, what each disease area needs to adapt, and where local markets need permission to flex.
One market may need to defend outcomes against simpler competitor frames. Another may need help with eligibility, documentation, cost, eosinophil testing, and treatment responsibility.
A global agenda only works if local teams can use it in their own competitive reality.
It needs to know: what is the strategic core, where can disease areas and markets flex, and what support will help local teams execute with confidence?
A working map across science, patient value, and trust — to test, not assume.
Broad science story through epithelium, alarmins, mucus, and remission.
TSLP / IL-33, epithelial health, mucus biology, clinical remission, broad efficacy, and upper / lower airway connection.
Simple clinical action through continuity, convenience, and control.
IL-5 continuity, Nucala / Exdensur, dosing convenience, hospitalisation, disease stability, and early treatment cues.
Evidence-backed Type 2 respiratory leadership.
Proven Type 2 science, broad respiratory evidence, patient impact, and clinical action across Asthma and COPD.
The open space on the portfolio-vision ground.
The space where science, patient value, and trusted clinical action come together as one Respiratory Vision.
A working hypothesis based on current competitive intelligence — to be validated through the research.